Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer

被引:44
作者
Poettgen, Christoph [1 ]
Theegarten, Dirk [5 ]
Eberhardt, Wilfried [2 ]
Levegruen, Sabine [1 ]
Gauler, Thomas [2 ]
Krbek, Thomas
Stamatis, Georgios [6 ]
Teschler, Helmut [7 ]
Kuehl, Hilmar [3 ]
Bockisch, Andreas [4 ]
Stuschke, Martin [1 ]
机构
[1] Univ Duisburg Essen, Dept Radiotherapy, DE-45122 Essen, Germany
[2] Univ Duisburg Essen, Dept Intenal Med Canc Res, DE-45122 Essen, Germany
[3] Univ Duisburg Essen, Dept Diagnost & Intervent Radiol, DE-45122 Essen, Germany
[4] Univ Duisburg Essen, Dept Nucl Med, DE-45122 Essen, Germany
[5] Univ Duisburg Essen, Inst Pathol & Neuropathol, DE-45122 Essen, Germany
[6] Univ Duisburg Essen, Dept Thorac Surg, DE-45122 Essen, Germany
[7] Univ Duisburg Essen, Dept Pulmonol, DE-45122 Essen, Germany
关键词
chemoradiotherapy; dual-modality PET/CT; locally advanced non-small cell lung cancer; macrophage infiltration; neoadjuvant;
D O I
10.1159/000134474
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Prediction of histopathological response with PET/CT scans after neoadjuvant chemoradiotherapy is limited by confounding factors which have been evaluated in this analysis. Methods: F-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT findings [standard uptake value (SUV), residual tumor volume] were correlated with histopathological parameters of the resection specimens (tumor cell density, necrosis, scar, macrophage infiltration) in patients with locally advanced non-small cell lung cancer (stage IIIA/IIIB) after neoadjuvant induction chemotherapy (platinum-based doublet) and concurrent chemoradiotherapy (cisplatin/vinorelbine/ 45 Gy). Results: Sixty patients [40 male/20 female, median age 56 years (34-78)] completed induction therapy, 46 patients (stage IIIA/IIIB: 16/30; squamous cell carcinoma 41%, adenocarcinoma 48%, large cell carcinoma 11%) were resected. Pathologic complete response of the primary tumor was observed in 19 patients (41%) with a broad range of SUVmean (0.4-9.8, mean 3.0) after neoadjuvant therapy. A high rate of histopathological complete remissions (44%) was observed in tumors with a postinduction SUV > 2.5 and volumes larger than the median (7.9 cm(3)) before resection. SUVmean was positively correlated with the macrophage score (r = 0.39, p = 0.007) and tumor cell density (r = 0.32, p = 0.03). Conclusions: These observations suggest that postinduction FDG uptake should be interpreted with caution in larger residual tumor volumes, since high SUV levels may be due to macrophage infiltration and not viable tumor tissue. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:316 / 323
页数:8
相关论文
共 50 条
  • [41] Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer
    Fujiwara, Masayuki
    Doi, Hiroshi
    Igeta, Masataka
    Suzuki, Hitomi
    Kitajima, Kazuhiro
    Tanooka, Masao
    Ishida, Toshihisa
    Wakayama, Tsukasa
    Yokoi, Takashi
    Kuribayashi, Kozo
    Kijima, Takashi
    Hashimoto, Masaki
    Kondo, Nobuyuki
    Matsumoto, Seiji
    Hasegawa, Seiki
    Kamikonya, Norihiko
    Yamakado, Koichiro
    ANTICANCER RESEARCH, 2021, 41 (11) : 5793 - 5802
  • [42] A study about different findings of PET-CT between neoadjuvant and non-neoadjuvant therapy: SUVmax is not a reliable predictor of lymphatic involvement after neoadjuvant therapy for esophageal cancer
    Park, Jae Kil
    Kim, Jae Jun
    Moon, Seok Whan
    JOURNAL OF THORACIC DISEASE, 2016, 8 (05) : 784 - 794
  • [43] Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
    Luis A. Godoy
    Joy Chen
    Weijie Ma
    Jag Lally
    Kyra A. Toomey
    Prabhu Rajappa
    Roya Sheridan
    Shirish Mahajan
    Nicholas Stollenwerk
    Chinh T. Phan
    Danny Cheng
    Robert J. Knebel
    Tianhong Li
    Biomarker Research, 11
  • [44] Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
    Godoy, Luis A.
    Chen, Joy
    Ma, Weijie
    Lally, Jag
    Toomey, Kyra A.
    Rajappa, Prabhu
    Sheridan, Roya
    Mahajan, Shirish
    Stollenwerk, Nicholas
    Phan, Chinh T.
    Cheng, Danny
    Knebel, Robert J.
    Li, Tianhong
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [45] Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
    Shen, Jie
    Gu, Linping
    Qi, Yuwen
    Yao, Yaxian
    Lu, Shun
    Chen, Zhiwei
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] Metabolic responses in non-small cell lung cancer after hypofractionated stereotactic radiotherapy PET and Hypofractionated Radiotherapy
    Ursino, S.
    Fiorica, F.
    Colosimo, C.
    Micucci, M.
    Stefanelli, A.
    Berretta, M.
    Panareo, S.
    De Biasi, V.
    Feggi, L. M.
    Zini, G.
    Cartei, F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2012, 16 (06) : 755 - 762
  • [47] Gemcitabine combined with cisplatin as neoadjuvant chemotherapy in stage IB-IIIA non-small cell lung cancer
    Davidov, Mikhail I.
    Polotzky, Boris E.
    Marenich, Aleksander F.
    Orlov, Sergey V.
    Lazarev, Aleksander F.
    Skryabina, Lyudmila S.
    Pavlushkov, Eugeniy V.
    Semenchenya, Vladimir A.
    Brichkova, Olga Y.
    Karaseva, Vera V.
    ANTI-CANCER DRUGS, 2011, 22 (06) : 569 - 575
  • [48] Radiotherapy of non-small cell lung cancer
    Kleine, P.
    Flentje, M.
    PNEUMOLOGE, 2016, 13 (04): : 241 - +
  • [49] Adjuvant Treatment Options after Neoadjuvant Chemotherapy Combined with Immunotherapy and Surgery in Patients with Non-Small Cell Lung Cancer
    Li, Y.
    Zhao, J.
    Li, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S568 - S568
  • [50] Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis
    Ge, Sa
    Huang, Chenjun
    JOURNAL OF THORACIC DISEASE, 2022, 14 (02) : 333 - 342